Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/10/15 | Current report filing |
|
3 | ||
| 06/04/15 | Post-effective amendment to a registration statement that is not immediately effective upon filing |
|
34 | ||
| 05/18/15 | Definitive proxy statements |
|
37 | ||
| 05/13/15 | Quarterly report pursuant to Section 13 or 15(d) |
|
 |
44 | |
| 05/12/15 | Current report filing |
|
10 | ||
| 05/08/15 | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
8 | ||
| 04/21/15 | Notice of termination of registration of a class of securities under Section 12(b) |
|
2 | ||
| 04/02/15 | Confidential treatment order |
|
1 | ||
| 03/30/15 | Notice of Effectiveness |
|
1 | ||
| 03/30/15 | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
5 |